Drugs / trivalent inactivated influenza vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06987942 Comparator | Sep → Nov 2024 | chickenpox | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trivalent inactivated influenza vaccine | “The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and...” NCT06987942 ↗ |
| Known as | TIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06987942 ↗ |
| Modality | Vaccine | “trivalent inactivated influenza vaccine” NCT06987942 ↗ |